Tonix Pharmaceuticals Holding - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TNXP Nasdaq 8731 https://www.tonixpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting - Jun 5th, 2023 11:00 am
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress - May 31st, 2023 11:00 am
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention - May 30th, 2023 11:00 am
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - May 25th, 2023 8:05 pm
Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - May 25th, 2023 11:00 am
Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit - May 24th, 2023 11:00 am
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases - May 23rd, 2023 11:00 am
Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin) - May 22nd, 2023 11:00 am
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference - May 18th, 2023 11:00 am
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression - May 17th, 2023 11:00 am
Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split - May 9th, 2023 5:00 pm
Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights - May 8th, 2023 11:00 am
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant - May 4th, 2023 11:00 am
TNXP: Phase 2 Trial of TNX-601 ER Enrolling; New Treatment Concept in Depression… - May 1st, 2023 3:35 pm
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US - Apr 27th, 2023 12:00 pm
Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation - Apr 24th, 2023 3:34 pm
Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023 - Apr 19th, 2023 11:00 am
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival - Apr 17th, 2023 11:00 am
Tonix Pharmaceuticals Fast Forwards Its Fibromyalgia, Migraine Studies - Apr 13th, 2023 6:12 pm
Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs - Apr 13th, 2023 11:00 am